AL Amyloidosis clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

    open to eligible people ages 18-120

    Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

    Los Angeles, California and other locations

Our lead scientists for AL Amyloidosis research studies include .

Last updated: